Why Are Fluorinated Drugs Essential in Modern Pharmacotherapy?
The integration of fluorine atoms within active pharmaceutical ingredients remains a potent technique in medicinal chemistry that improves their pharmacological attributes. The incorporation of one or more fluorine atoms and fluorinated groups (CF3 or -F) into drug structures makes these drugs essential in development because of fluorine's special electronegativity, improved metabolic stability, and increased lipophilicity. In recent years, the U.S. Food and Drug Administration (FDA) has approved more new molecular entities (NMEs) that feature fluorine within their molecular structures across multiple therapeutic areas, including oncology and infectious diseases, as well as neurological disorders and cardiovascular conditions.
Alfa Chemistry functions as a leading provider of fluorinated pharmaceutical intermediates and APIs by supplying researchers and manufacturers with a broad range of high-purity fluorinated building blocks to fulfill industrial requirements.
How Has the FDA's Fluorinated Drug Approval Landscape Evolved Between 2018 and 2022?
Between 2018 and 2022, the FDA approved 54 fluorinated small-molecule drugs, accounting for approximately 30% of all small-molecule NMEs during that period. This trend reflects the ongoing shift toward designing molecules with tailored physicochemical and pharmacokinetic properties enabled by strategic fluorination. Among these approvals, drugs containing fluorinated aromatic rings, trifluoromethyl (CF3) groups, and fluoroalkyl chains dominated. These fluorinated fragments are not merely structural novelties but critical to drug performance - improving membrane permeability, receptor binding affinity, and resistance to metabolic degradation.
Figure 1. FDA-approved fluorinated drugs[1].
Notably, the number of fluorinated drugs peaked in 2020, corresponding to the urgent development of therapeutics during the COVID-19 pandemic. Compounds such as Remdesivir (Veklury), a fluorinated nucleotide analog antiviral, exemplify how fluorinated structures can rapidly be adapted for emerging threats.
Table 1: U.S. FDA-Approved fluorinated drugs (2018-2022)[1].
Therapeutic Areas | Drug | Approval Date | Composition | Indication | Drug Mechanism |
Anti-cancer | Erleada | 2/14/2018 | Apalutamide | Prostate cancer | Androgen receptor inhibitor |
Mektovi | 6/27/2018 | Binimetinib | BRAF V600E– or V600K–positive metastatic melanoma (in combination with Braftovi) | MEK1/2 inhibitor | |
Braftovi | 6/27/2018 | Encorafenib | BRAF V600E– or V600K–positive metastatic melanoma (in combination with Mektovi) | BRAF inhibitor | |
Tibsovo | 7/20/2018 | Ivosidenib | Acute myeloid leukemia | IDH1 inhibitor | |
Vizimpro | 9/27/2018 | Dacomitinib | Non-small-cell lung cancer | Irreversible EGFR inhibitor | |
Lorbrena | 11/2/2018 | Lorlatinib | ALK-positive metastatic non-small-cell lung cancer | ALK inhibitor | |
Talzenna | 10/16/2018 | Talazoparib | Breast cancer with germline BRCA mutations | PARP inhibitor | |
Vitrakvi | 11/26/2018 | Larotrectinib | NTRK gene fusion–positive solid tumors | TRK inhibitor | |
Piqray | 5/24/2019 | Alpelisib | Breast cancer | PI3Ka inhibitor | |
Xpovio | 7/3/2019 | Selinexor | Multiple myeloma | Nuclear export inhibitor | |
Turalio | 8/2/2019 | Pexidartinib | Symptomatic tenosynovial giant-cell tumors | CSF1R, KIT, and FLT3-ITD inhibitor | |
Rozlytrek | 8/15/2019 | Entrectinib | Non-small-cell lung cancer whose tumors are ROS1 positive | ROS1 and NTRK inhibitor | |
Ayvakit | 1/9/2020 | Avapritinib | Gastrointestinal-stromal tumor | PDGFRA and KIT inhibitor | |
Isturisa | 3/6/2020 | Osilodrostat | Cushing's disease in adults | Cortisol synthesis inhibitor | |
Koselugo | 4/10/2020 | Selumetinib | Neurofibromatosis type 1, a genetic disorder that causes tumors to grow on nerves | MEK1/2 inhibitor | |
Pemazyre | 4/17/2020 | Pemigatinib | Cholangiocarcinoma, a rare form of cancer that forms in bile ducts | FGFR inhibitor | |
Tabrecta | 5/6/2020 | Capmatinib | Non-small-cell lung cancer | MET inhibitor | |
Qinlock | 5/15/2020 | Ripretinib | Gastrointestinal-stromal tumors | KIT and PDGFRA kinase inhibitor | |
Cerianna | 5/20/2020 | Fluoroestrdiol F18 | Diagnostic imaging agent for certain patients with breast cancer | Radiodiagnostic | |
Inqovi | 7/7/2020 | Decitabine and cedazuridine | Myelodysplastic syndromes | Nucleoside metabolic inhibitor and cytidine deaminase inhibitor | |
Gavreto | 9/4/2020 | Pralsetinib | Non-small-cell lung cancer | RET fusion inhibitor | |
Orladeyo | 12/4/2020 | Berotralstat | Prevention of hereditary angioedema | Plasma kallikrein inhibitor | |
Orgovyx | 12/18/2020 | Relugolix | Prostate cancer | GnRH receptor antagonist | |
Ukoniq | 2/5/2021 | Umbralisib | Marginal zone lymphoma or follicular lymphoma | Kinase inhibitor | |
Pepaxto | 2/26/2021 | Melphalan flufenamide | Relapsed or refractory multiple myeloma | DNA alkylation | |
Pylarify | 5/26/2021 | Piflufolastat F-18 | Identification of lesions positive for prostate-specific membrane antigen in people with prostate cancer | Binds to malignant prostate cancer cells | |
Lumakras | 5/28/2021 | Sotorasib | Non-small-cell lung cancer | KRAS G12C inhibitor | |
Welireg | 8/13/2021 | Belzutifan | Von Hippel-Lindau disease | Hypoxia-inducible factor-2α inhibitor | |
Scemblix | 10/29/2021 | Asciminib | Philadelphia chromosome–positive chronic myeloid leukemia | Kinase inhibitor | |
Krazati | 12/12/2022 | Adagrasib | KRAS G12C–mutated non-small-cell lung cancer | Irreversible inhibitor of KRAS G12C | |
Infectious diseases | Biktarvy | 2/7/2018 | Bictegravir Sodium, Emtricitabine and Tenofovir alafenamide fumarate | HIV infection | Integrase strand transfer inhibitor, two HIV nucleoside analog reverse transcriptase inhibitors |
Akynzeo | 4/19/2018 | Netupitant and palonosetron | Nausea | NK1 receptor antagonist and 5-HT3 receptor antagonist | |
TPOXX | 7/13/2018 | Tecovirimat | Smallpox | Orthopoxvirus VP37 envelope wrapping protein inhibitor | |
Krintafel | 7/20/2018 | Tafenoquine | Malaria relapse prevention | 8-Aminoquinoline antiparasitic | |
Xerava | 8/27/2018 | Eravacycline | Complicated intra-abdominal infections | Antibiotic, binds 30S ribosomal subunit to block protein synthesis | |
Pifeltro | 8/30/2018 | Doravirine | HIV-1 infection | Antiviral, reverse transcriptase inhibitor | |
Xofluza | 10/24/2018 | Baloxavir marboxil | Influenza | Antiviral inhibitor of influenza polymerase acidic protein | |
Pretomanid | 8/14/2019 | Pretomanid | Treatment-resistant tuberculosis | Nitroimidazooxazine antimycobacterial | |
Cabenuva | 1/21/2021 | Cabotegravir and Rilpivirine | HIV | HIV-1 antiretrovirals | |
Voquezna | 5/3/2022 | Vonoprazan, Amoxicillin, and Carithromycin | Helicobacter Pylori Infection | Proton pump inhibitor and antimicrobials | |
Vivjoa | 4/26/2022 | Oteseconazole | Recurrent vulvovaginal candidiasis | 14α-Demethylase inhibitor | |
Sunlenca | 12/22/2022 | Lenacapavir | HIV infections in adults that cannot be successfully treated with other available treatments | HIV-1 antiretroviral agent | |
Central nervous system (CNS) disorders | Mayzent | 3/26/2019 | Siponimod | Relapsing forms of multiple sclerosis | Selective sphingosine 1-phosphate receptor modulator |
Fluorodopa F-18 | 10/10/2019 | Fluorodopa F-18 | Diagnostic for Parkinson's disease | Positron-emission tomography | |
Reyvow | 10/11/20219 | Lasmiditan | Acute migraines | 5-HT1F receptor agonist | |
Caplyta | 12/20/2019 | Lumateperone tosylate | Schizophrenia | Unknown | |
Dayvigo | 12/20/2019 | Lemborexant | Insomnia | Orexin receptor antagonist | |
Ubrelvy | 12/23/2019 | Ubrogepant | Acute migraines | CGRP receptor antagonist | |
Nurtec ODT | 2/27/2020 | Rimegepant | Migraine | Calcitonin gene-related peptide receptor antagonist | |
Tauvid | 5/28/2020 | Flortaucipir F18 | Alzheimer's disease diagnostic | Radiodiagnostic | |
Qulipta | 9/28/2021 | Atogepant | Episodic migraines | Calcitonin gene–related peptide receptor antagonist | |
Verquvo | 1/19/2021 | Vericiguat | Chronic heart failure | Soluble guanylate cyclase stimulator | |
Other diseases | Symdeko | 2/13/2018 | Tezacaftor and Ivacaftor | Cystic Fibrosis | CFTR corrector and CFTR potentiator |
Tavalisse | 4/17/2018 | Fostamatinib | Chronic immune thrombocytopenia | SYK inhibitor | |
Orilissa | 7/23/2018 | Elagolix sodium | Endometriosis | GnRH receptor antagonist | |
Rinvoq | 8/16/2019 | Upadacitinib | Rheumatoid arthritis | JAK inhibitor | |
Trikafta | 10/21/2019 | Tezacaftor, Ivacaftor and Elexacaftor | Cystic Fibrosis | CCFTR corrector, CFTR potentiator and CFTR corrector | |
Tavneos | 10/7/2021 | Avacopan | Severe active antineutrophil cytoplasmic autoantibody–associated vasculitis | C5a receptor antagonist |
What Structural Benefits Do Fluorine Atoms Offer in Drug Design?
Fluorine atoms influence molecular behavior in several scientifically advantageous ways:
Effect | Mechanism | Therapeutic Benefit |
Increased lipophilicity | Fluorine enhances hydrophobic interactions | Improved membrane permeability and oral bioavailability |
Metabolic stability | C–F bonds resist oxidative degradation | Longer half-life, fewer dosing intervals |
Enhanced binding affinity | Alters pKa, dipole moments, and hydrogen bonding | Greater target selectivity and potency |
Conformational restriction | Influences torsional angles in bioactive conformations | Better receptor fit and efficacy |
These properties explain why fluorinated drugs frequently show improved ADMET (absorption, distribution, metabolism, excretion, toxicity) profiles, making them highly favored in preclinical and clinical drug pipelines.
What Infectious Diseases Are Targeted by Fluorinated Pharmaceuticals?
Between 2018 and 2022, twelve FDA-approved fluorinated drugs targeted a broad spectrum of infectious diseases, ranging from HIV and smallpox to malaria and SARS-CoV-2.
- HIV/AIDS: Biktarvy, Cabenuva, Pifeltro, and Sunlenca serve as multi-mechanistic antiretrovirals. Fluorine improves intracellular half-life and resistance profiles by stabilizing conformational states of integrase and reverse transcriptase binding pockets.
- Smallpox and Viral Infections: TPOXX (Tecovirimat), a VP37 protein inhibitor, exemplifies fluorine-enabled potency against orthopoxviruses. Paxlovid (Nirmatrelvir + Ritonavir), used for COVID-19, utilizes fluorinated moieties to increase protease binding and reduce metabolic degradation.
- Antifungals and Antimalarials: Brexafemme (Ibrexafungerp) and Krintafel (Tafenoquine) are fluorinated agents offering new mechanisms for fungal and parasitic disease control. Their chemical resilience, partly imparted by fluorine, is critical in resisting enzymatic breakdown and prolonging systemic activity.
Figure 2. Chemical structures of drugs approved by the FDA for various types of cancer from 2018 to 2022[1].
Figure 3. Chemical structures of infectious disease drugs approved by the FDA from 2018 to 2022[1].
How Do Fluorinated Functional Groups Influence Drug Behavior?
Fluorinated Moiety | Representative Drugs | Pharmacokinetic Effect |
Aromatic -F or -CF3 | Drugs 1–8, 10–19, 22–24, 27 | Improved metabolic stability, increased protein binding affinity |
Geminal -CF2 | Drugs 4, 20, 29 | Enhanced potency and metabolic resistance |
Aliphatic -CF3 | Drugs 9, 12 | Reduced microsomal clearance |
Vicinal -F2 | Drug 28 | Increased stability and potency |
Vinylic -F | Drug 30 | Optimized binding while retaining metabolic robustness |
These substitutions enhance molecular conformation, binding kinetics, and receptor selectivity. The trifluoromethyl (-CF3) group is particularly effective in modulating lipophilicity and electronic distribution, while gem-difluoro groups help lock bioactive conformations, critical for kinase inhibitors and protease blockers.
Figure 4. Chemical structures of central nervous system drugs approved by the FDA from 2018 to 2022[1].
Figure 5. Chemical structures of drugs approved by the FDA from 2018 to 2022 for other diseases[1].
FAQs about FDA-Approved Fluorinated Drugs
Q1: What makes fluorine such an effective element in drug design?
Fluorine's high electronegativity and small atomic size allow it to influence molecular behavior without adding bulk. It can improve metabolic stability, target binding, and drug absorption.
Q2: How many fluorinated drugs were approved by the FDA from 2018 to 2022?
A total of 42 fluorinated drugs were approved during this period—30 for cancer treatment and 12 for infectious diseases.
Q3: Are any fluorinated drugs used for diagnostic purposes?
Yes, Pylarify and Cerianna are radiopharmaceuticals labeled with fluorine-18 (18F) used in PET imaging for prostate and breast cancers, respectively.
Q4: What types of cancers are treated with fluorinated drugs?
Fluorinated drugs are used to treat prostate, breast, lung, melanoma, leukemia, gastrointestinal stromal tumors, and others.
Q5: How does fluorine affect a drug's metabolism?
Fluorine often reduces enzymatic degradation, increases the drug's half-life, and enhances bioavailability by blocking metabolic hotspots.
Q6: Can fluorinated drugs combat viral infections like HIV or COVID-19?
Yes, drugs like Biktarvy, Sunlenca, and Paxlovid are fluorinated and have demonstrated efficacy against HIV and SARS-CoV-2.
Q7: What role does Alfa Chemistry play in fluorinated drug development?
Alfa Chemistry supplies fluorinated intermediates, radiolabeling precursors, and custom synthesis services critical to developing next-generation fluorinated drugs.
Reference
- Ali S., et al. Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018–2022). European Journal of Medicinal Chemistry. 2023, 256, 115476.